French parliament OKs hep C drug rebate scheme
This article was originally published in Scrip
Executive Summary
The company rebate mechanism for the expensive new hepatitis C drugs including Gilead's Sovaldi will now be enshrined in French law, after the lower house of the parliament approved the social security financing bill (PLFSS) for 2015.
You may also be interested in...
Hepatitis C And PrEP Bring More Funding Headaches For NHS England
Drugs for hepatitis C and HIV prevention are causing funding problems for the NHS in England as court battles loom and innovation continues to bring more cost pressures.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.